Orchard Therapeutics plc
ORTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.06 | 0.22 | 0.09 |
| FCF Yield | -174.23% | -78.43% | -32.34% | -13.30% |
| EV / EBITDA | -4.58 | -4.70 | -2.92 | -7.98 |
| Quality | ||||
| ROIC | -15.86% | -12.70% | -64.25% | -48.82% |
| Gross Margin | 65.17% | 53.21% | 66.97% | 67.97% |
| Cash Conversion Ratio | 0.50 | 0.87 | 0.83 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 39.11% | -42.29% | 7.72% | – |
| Free Cash Flow Growth | 35.71% | 7.64% | 18.51% | -67.87% |
| Safety | ||||
| Net Debt / EBITDA | 1.28 | -0.10 | -0.02 | -0.16 |
| Interest Coverage | -33.86 | -53.32 | -67.43 | -112.40 |
| Efficiency | ||||
| Inventory Turnover | 0.72 | 0.11 | 1.29 | 0.00 |
| Cash Conversion Cycle | -134.99 | 11,428.17 | -911.51 | -3,055.21 |